GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

briakinumab   Click here for help

GtoPdb Ligand ID: 9213

Synonyms: ABT-874 | J-695 | J695 | Ozespa
Immunopharmacology Ligand
Compound class: Antibody
Comment: Briakinumab is a recombinant, fully human, IgG1 investigational monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23. Peptide sequences matching those of briakinumab are claimed in patent US6914128 'Human antibodies that bind human IL-12 and methods for producing' [2].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pericyazine

Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-12B Primary target of this compound Hs Antibody Binding >10.0 pKd - 2
⤷ pKd >10.0 (Kd <1x10-10 M) [2]